Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its antibody drug conjugate (ADC) 7MW3711, which targets B7-H3. The molecule is intended to be assessed as a treatment for a broad range of advanced solid tumors.
Upon injection into the human body, 7MW3711 is designed to bind with antigens present on the surface of tumor cells and penetrate these cells. Through a specific enzymatic hydrolysis process, small molecule cytotoxic drugs are released, enabling precise tumor cell killing.
IDDC represents a new generation ADC fixed-point coupling technology platform, independently developed by Mabwell. This platform comprises multiple systematic core patented technologies, including fixed-point coupling process DARfinity, fixed-point connector IDconnect, new loaded molecule Mtoxin, and conditional release structure LysOnly. The platform’s efficacy has been validated in multiple investigational products. Notably, 9MW2921, an ADC targeting Trop-2, has also been granted approval for study in advanced solid tumors.- Flcube.com
